Abstract
34O ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss: Results from the ENGOT/GYN1/NCRI ATARI trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have